NEWS

Combining machine learning tools for medical imaging with genetic sequencing nets Sophia Genetics $110M

October 1, 2020

With the closure of its sixth venture capital round, the Swiss health data firm Sophia Genetics added another $110 million to its coffers in a series F financing led by aMoon and Hitachi Ventures.

Read More

Venture capitalists find more to Israel than Zionism

September 30, 2020

Not all olim arrive in Israel to serve in the IDF or go to university. In the case of two aMoon executives, coming to Israel was a way to advance their careers in venture capital health investments while also reaching the goal of living in the Jewish state.

Read More

Adicet Announces Completion of Merger with resTORbio

September 15, 2020

Adicet Bio, Inc., a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, today announced the completion of its previously announced merger with resTORbio, Inc

Read More

Seer Announces Spin Out of PrognomIQ with $55 Million Initial Financing

September 15, 2020

Seer, Inc., an aMoon2 portfolio company focused on enabling exceptional scientific outcomes through the power of unbiased, deep, rapid and scalable proteomics information, today announced that it has spun out and completed the initial financing of $55M for a newly formed healthcare company, PrognomIQ, Inc.

Read More

MiNA Therapeutics Secures £23 Million Series A Financing to Advance First-in-Class Activating RNA-Based Therapeutics

September 10, 2020

MiNA Therapeutics, the pioneer in RNA activation therapeutics, announced today the completion of a £23 million ($30 million) Series A equity financing led by aMoon, Israel’s largest healthtech and life sciences venture fund.

Read More

MOBILion Closes $35M Series B Financing Round

August 17, 2020

aMoon leads round to expand product portfolio and advance commercial efforts for MOBILion’s SLIM technology for biotherapeutics characterization and novel biomarker discovery

Read More

Roche invests millions in Israel’s health tech sector

August 11, 2020

has entered into a partnership agreement with aMoon, an Israeli venture capital company focused on health technology and science. The “StarFinder Lab” collaboration is aiming to help young startups develop innovative diagnostic tools to tackle global health care challenges.

Read More

Israel’s Largest Health VC Boosts Fund to $750 Million on Virus

July 22, 2020

Israel’s largest venture capital investor in life sciences, AMoon, boosted the size of its biggest fund to $750 million after demand for new health-care technology rose during the coronavirus pandemic.

Read More

Israeli healthtech VC aMoon Velocity invests $6 million in Nectin Therapeutics

July 15, 2020

Israel’s largest healthtech venture fund, aMoon, announced an investment of $6 million in Nectin Therapeutics Ltd. via its early-stage fund, aMoon Velocity.

Read More

Israel Bolsters Antibody Tests as Second Virus Wave Threatens

July 3, 2020

Israel is fortifying its national survey of exposure to the coronavirus as a second wave of infections threatens to plunge the country back into lockdown.

Read More

‘Covid Put Everything On Steroids,’ Says Prominent Healthtech Investor

June 30, 2020

When VC aMoon was established in 2017, “the premise was to invest heavily in the convergence of technology and biology, healthcare and data,” says Dr. Yair Schindel, its Managing Partner.

Read More

NIH Partners with Israeli Startup to Generate Synthetic COVID-19 Data

June 18, 2020

Through a new partnership, the National Institutes of Health will harness Israeli startup MDClone’s platform to generate computationally-derived synthetic data directly from clinical health data aggregated across the U.S., to underpin and advance research in the fight against COVID-19.

Read More

Curesponse Secures $6M Series A for Breakthrough Precision Medicine

June 5, 2020

Curesponse, a cancer precision medicine company, has raised $6M from investors including NCL Technology Ventures (UK) and aMoon (Israel) for scaling clinical trials and international expansion to the UK.

Read More

Zebra Medical Vision Secures its 5th FDA Clearance, Making Its Vertebral Compression Fractures AI Solution Available in the U.S.

May 18, 2020

Zebra Medical Vision, the deep-learning medical imaging analytics company, announces today its fifth FDA 510(k) clearance for its Vertebral Compression Fractures (VCF) product.

Read More

Ayala Pharmaceuticals Announces Pricing of Initial Public Offering

May 7, 2020

Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations, today announced the pricing of its initial public offering of 3,666,667 shares of common stock at a public offering price of $15.00 per share, before underwriting discounts and commissions.

Read More

Herd Immunity, or Big 2nd Wave? Israel Antibody Testing Hopes to Find Out

May 5, 2020

Yair Schindel, aMoon Managing Partner and a member of Israel’s health ministry task force on COVID-19, spoke to the The New York Times about the pandemic and Israel’s latest initiative to conduct nationwide serological testing on 100,000 citizens. Yair outlined the two likely scenarios Israel might find out as a result of the antibody testing.

Read More

resTORbio and Adicet Bio Announce Merger Agreement to Advance Allogeneic Gamma Delta CAR-T Cell Therapy Technology

April 29, 2020

resTORbio, Inc. (Nasdaq: TORC) and Adicet Bio, Inc., a privately-held biopharmaceutical company, today announced that they have entered into a definitive merger agreement to create a combined publicly-traded biotechnology company focused on the development of Adicet’s off-the-shelf allogeneic gamma delta T cell therapies for oncology and other indications.

Read More

Ibex Obtains CE-IVD Mark for AI-powered Cancer Detection

February 27, 2020

Ibex’s Galen™ Prostate solution demonstrates outstanding results in a blinded study and supports pathologists in providing accurate diagnosis, enhanced lab efficiency and quality control.

Read More

Karius raises $165 million for its liquid biopsy technology identifying diseases with a blood draw

February 24, 2020

While the new money may have been raised under the looming threat of Covid 19, the company’s technology is already being used to test for infection-causing pathogens in immunocompromised pediatric patients, and for potential causes of complex pneumonia, fungal infections and endocarditis, according to a statement from the company.

Read More

Interview: Healthtech Is Israel’s Next Growth Engine, Says Venture Capitalist

February 21, 2020

Yair Schindel was a decorated army medic, a doctor, an entrepreneur, and the head of Israel’s National Digital Bureau. Now, he manages Israeli venture capital fund aMoon and wants to turn Israel into a healthtech empire.

Read More